zileuton has been researched along with Adenocarcinoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, W; Ding, XL; Qu, LS; Wu, SB; Zhang, H; Zhang, HF; Zhou, GX | 1 |
| Achucarro, P; Guski, H; Heinicken, D; Jacobi, CA; Kilian, M; Müller, JM; Schimke, I; Wenger, FA | 1 |
| Beer, DG; Chen, X; Giordano, TJ; Jin, Z; Lin, Y; Lubet, RA; Shih, WC; Sood, S; Wang, P; Wang, S; Wu, N; Yang, CS | 1 |
| Hussey, HJ; Tisdale, MJ | 1 |
4 other study(ies) available for zileuton and Adenocarcinoma
| Article | Year |
|---|---|
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms | 2015 |
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Celecoxib; Cricetinae; Glutathione; Hydroxyurea; Incidence; Lipoxygenase Inhibitors; Male; Mesocricetus; Pancreas; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2002 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Body Weight; Celecoxib; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Hydroxyurea; Immunohistochemistry; Leukotriene B4; Lipoxygenase Inhibitors; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2004 |
Inhibition of tumour growth by lipoxygenase inhibitors.
Topics: Adenocarcinoma; Administration, Oral; Analysis of Variance; Animals; Benzeneacetamides; Cell Division; Colonic Neoplasms; Hydroxamic Acids; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mice; Neoplasm Transplantation; Treatment Outcome; Tumor Cells, Cultured | 1996 |